Unstable beta globin chain variant disease

Unstable beta globin chain variant disease, also known as unstable hemoglobin disease due to beta-globin chain variants, is a group of rare hemolytic anemias caused by mutations in the HBB gene (encoding the beta-globin chain of hemoglobin). These mutations produce structurally abnormal beta-globin proteins that are inherently unstable, leading to premature denaturation and precipitation of hemoglobin within red blood cells. The precipitated hemoglobin forms inclusions known as Heinz bodies, which damage the red cell membrane and lead to premature destruction of red blood cells (hemolysis). The disease primarily affects the hematologic system. Key clinical features include chronic hemolytic anemia of variable severity, jaundice, splenomegaly, and dark urine (due to the excretion of breakdown products of unstable hemoglobin, sometimes called dipyrroluria). Some patients may experience hemolytic crises triggered by oxidant drugs, infections, or fever. The severity of the condition varies widely depending on the specific mutation involved — some variants cause mild, well-compensated hemolysis, while others result in severe transfusion-dependent anemia. Management is largely supportive. Patients are advised to avoid oxidant drugs and other triggers of hemolytic crises. Folic acid supplementation is commonly recommended to support red blood cell production. Blood transfusions may be required during severe hemolytic episodes or in cases of chronic severe anemia. Splenectomy may be considered in patients with significant splenomegaly or severe transfusion-dependent anemia, though the response is variable. Over 100 different unstable beta-globin variants have been described in the medical literature, making this a heterogeneous group of disorders classified under beta-thalassemia (ICD-10: D56.1).

Common questions about Unstable beta globin chain variant disease